Skip to main content

Table 1 Baseline patient characteristics

From: Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Characteristic (N = 855) Patients aged > 70 years Patients aged ≤ 70 years
Total number of patients 193 662
Median age, years (range) 75 (71–88) 55 (16–70)
Male/female, n (%) 112 (58)/81 (42) 348 (53)/314 (47)
ECOG performance status, n (%)   
 0 105 (54) 458 (69)
 1 83 (43) 184 (28)
 2 5 (3) 20 (3)
Time from diagnosis, months (range) 35 (3–280) 40 (3–280)
LDH level, n/n (%)a   
 < 1.10 ULN 108/175 (62) 336/545 (62)
 ≥ 1.10 ULN 67/175 (38) 209/545 (38)
Number of previous therapies, n (%)   
 1 128 (66) 369 (56)
 2 41 (21) 192 (29)
 ≥ 3 24 (13) 101 (15)
Previous therapy, n (%)   
 Dacarbazine 113 (59) 377 (57)
 Fotemustine 54 (28) 268 (41)
 Platinum-based chemotherapy 42 (22) 274 (41)
 Temozolomide 40 (21) 149 (23)
 Interferon 22 (11) 172 (26)
 BRAF inhibitor 8 (4) 51 (8)
Patients with brain metastases, n (%) 17 (9) 129 (20)
Patients with liver metastases, n (%) 75 (39) 264 (40)
  1. aLDH data unavailable for 135 patients.
  2. ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal.